Soubeyran et al. examined expression of ER, PR, pS2, c-erbB-2, and glutathione S-transferase π on core needle biopsies as potential markers to predict tumor regression in response to tamoxifen as neoadjuvant treatment [18]. This evidence concerns the gene HPGDS and neoplasm.